ClinicalTrials.gg

Program

omfiloctocog alfa

Also written as “Recombinant Human Coagulation FVIII”, “SCT800” and “SCT800 prophylaxis and treatment for bleeding events”.

Its studies are mostly in Hemophilia A, led by Sinocelltech Group.

Furthest: phase 4, since May 9, 20196 company-led studies, 2 open or runningNext primary completion: Dec 26, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinocelltech Group62 open or runningphase 4since May 9, 2019Aug 30, 2016Dec 26, 2028phase 3 · NCT07437404

Also a collaborator on its studies: Parexel and Q2 Solutions.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 30, 2016First study: phase 1 study in Hemophilia AFirst studyNCT02888223 · 16 enrolled · China
  2. Sep 28, 2016Phase 3 study in Hemophilia ANCT02921945 · 50 enrolled · China
  3. Jan 17, 2019Phase 3 study in Hemophilia ANCT03815318 · 73 enrolled · China
  4. May 9, 2019Phase 4 study in Hemophilia ANCT03947567 · 240 planned · China
  5. May 9, 2019Phase 3 study in Hemophilia ANCT03947320 · 70 enrolled
  6. Feb 9, 2026Phase 3 study in Hemophilia ANCT07437404 · 36 planned · China

Ahead

  1. Dec 26, 2028Primary completion: phase 3 study in Hemophilia ANCT07437404

TargetBeta

F8 →read by rule
“Coagulation factor VIII exogenous protein”ChEMBL 37, by rule

Other programs on F8

ProgramCompanyFurthest phaseStudies
antihemophilic factor, human recombinantruleTakedaphase 416
efanesoctocog alfaruleSanofiphase 412
lonoctocog alfaruleCSLphase 34

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07437404Hemophilia A · China3RecruitingDec 26, 202836
NCT03947567Hemophilia A · China4RecruitingApr 1, 2025240
NCT03947320Hemophilia A3UNKNOWNSep 20, 202070
NCT03815318Hemophilia A · China3CompletedJan 16, 202073
NCT02921945Hemophilia A · China3UNKNOWNDec 201750
NCT02888223Hemophilia A · China1UNKNOWNFeb 201716

How it is read

Names in the registry

  • “Recombinant Human Coagulation FVIII”, 3 entries
  • “SCT800”, 2 entries
  • “SCT800 prophylaxis and treatment for bleeding events”, 1 entry

Codes read as this program: SCT800.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
omfiloctocog alfa (Sinocelltech Group): development program | ClinicalTrials.gg